Unknown

Dataset Information

0

Discovery of DNA Topoisomerase I Inhibitors with Low-Cytotoxicity Based on Virtual Screening from Natural Products.


ABSTRACT: Currently, DNA topoisomerase I (Topo I) inhibitors constitute a family of antitumor agents with demonstrated clinical effects on human malignancies. However, the clinical uses of these agents have been greatly limited due to their severe toxic effects. Therefore, it is urgent to find and develop novel low toxic Topo I inhibitors. In recent years, during our ongoing research on natural antitumor products, a collection of low cytotoxic or non-cytotoxic compounds with various structures were identified from marine invertebrates, plants, and their symbiotic microorganisms. In the present study, new Topo I inhibitors were discovered from low cytotoxic and non-cytotoxic natural products by virtual screening with docking simulations in combination with bioassay test. In total, eight potent Topo I inhibitors were found from 138 low cytotoxic or non-cytotoxic compounds from coral-derived fungi and plants. All of these Topo I inhibitors demonstrated activities against Topo I-mediated relaxation of supercoiled DNA at the concentrations of 5-100 µM. Notably, the flavonoids showed higher Topo I inhibitory activities than other compounds. These newly discovered Topo I inhibitors exhibited structurally diverse and could be considered as a good starting point for the development of new antitumor lead compounds.

SUBMITTER: Xin LT 

PROVIDER: S-EPMC5532659 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Discovery of DNA Topoisomerase I Inhibitors with Low-Cytotoxicity Based on Virtual Screening from Natural Products.

Xin Lan-Ting LT   Liu Lu L   Shao Chang-Lun CL   Yu Ri-Lei RL   Chen Fang-Ling FL   Yue Shi-Jun SJ   Wang Mei M   Guo Zhong-Long ZL   Fan Ya-Chu YC   Guan Hua-Shi HS   Wang Chang-Yun CY  

Marine drugs 20170709 7


Currently, DNA topoisomerase I (Topo I) inhibitors constitute a family of antitumor agents with demonstrated clinical effects on human malignancies. However, the clinical uses of these agents have been greatly limited due to their severe toxic effects. Therefore, it is urgent to find and develop novel low toxic Topo I inhibitors. In recent years, during our ongoing research on natural antitumor products, a collection of low cytotoxic or non-cytotoxic compounds with various structures were identi  ...[more]

Similar Datasets

| S-EPMC8545810 | biostudies-literature
| S-EPMC5615061 | biostudies-literature
| S-EPMC5936786 | biostudies-literature
| S-EPMC4260913 | biostudies-literature
| S-EPMC7166849 | biostudies-literature
| S-EPMC2043263 | biostudies-literature
| S-EPMC6396084 | biostudies-literature
| S-EPMC6071756 | biostudies-literature
| S-EPMC4726279 | biostudies-literature
| S-EPMC7781311 | biostudies-literature